Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares
Nancy Andrews, a Director at Charles River Laboratories International (NYSE:CRL), sold 573 shares of the company's stock for a total of $163,442.52, reducing her ownership by 28.49%. The
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock
Shannon Parisotto, Executive Vice President at Charles River Laboratories International (NYSE:CRL), sold 2,039 shares of the company's stock for approximately $599,711. This transaction, executed under a Rule 10b5-1 trading plan, reduced her stake by nearly 30%. The company recently surpassed quarterly earnings and revenue expectations, reporting $3.02 EPS against a $2.77 consensus, and $1 billion in revenue, despite a year-over-year revenue decline and negative net margin.
Charles River (NYSE: CRL) director exercises options, sells 573 shares
Nancy C. Andrews, a director at Charles River Laboratories (CRL), reported exercising 573 stock options at $164.30 per share and immediately selling the acquired 573 common shares at $285.24 per share. After these transactions, she indirectly holds 3,964 common shares through a trust. The transaction was not executed under a Rule 10b5-1 trading plan.
Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan
Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories (NYSE: CRL), sold 2,039 shares of common stock at $294.12 per share, after exercising stock options at $194.12 per share. This transaction was conducted under a Rule 10b5-1 Trading Plan adopted on March 4, 2026. Following the sale, Parisotto's indirect holdings include 9,680 common shares by a trust and 28,510 common shares through Karpathos Investments LLC.
Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment
Charles River Laboratories (CRL) stock has reached a new 52-week high in August 2026, trading near $295. This surge is attributed to a new collaboration with Medigen Vaccine Biologics Corp. for a multivalent enterovirus vaccine and raised full-year 2026 guidance after strong Q2 results. The stock's performance highlights investor confidence in its growth prospects and specialized research services, despite trading significantly above some intrinsic valuation estimates.
Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com
Charles River Laboratories International Inc. (CRL) stock reached a new 52-week high of $294.68, reflecting a significant 90.12% increase over the past year. The company's stock has shown strong performance with an 82% return over the last year and a 72% gain in six months, driven by robust second-quarter 2026 earnings that surpassed analyst expectations. Analysts have consequently upgraded their ratings and price targets, despite InvestingPro suggesting potential overvaluation.
Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com
Charles River Laboratories International Inc. (CRL) stock reached a new 52-week high at $294.68, reflecting a significant 90.12% increase over the past year. Despite a recent loss per share, analysts predict a return to profitability in 2026, and the company recently surpassed Q2 2026 earnings and revenue expectations, leading to several analyst upgrades and increased price targets. InvestingPro suggests the stock might be overvalued at current levels.
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) are collaborating to advance MVC's next-generation multivalent enterovirus vaccine through the application of Next-Generation Sequencing (NGS) and other advanced analytical platforms. This partnership aims to accelerate vaccine development, ensure global regulatory readiness, and generate robust data for IND applications and future clinical development. Both companies plan to explore further collaborations on other vaccine programs to address global infectious diseases.
A new vaccine for several enteroviruses gets a testing partner
Charles River Laboratories (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) have announced a collaboration to accelerate the development of MVC's next-generation multivalent enterovirus vaccine. Charles River will use its Next-Generation Sequencing (NGS) and biologics testing expertise to support the vaccine's characterization, validation, and regulatory readiness. This partnership aims to advance the vaccine program efficiently, leveraging Charles River's global expertise in virology and non-clinical development.
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have announced a collaboration to advance MVC's next-generation multivalent enterovirus vaccine. Charles River will use its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support the Chemistry, Manufacturing, and Controls (CMC) activities and accelerate the vaccine's development and regulatory readiness. This partnership aims to combine Charles River's global biologics testing and non-clinical development capabilities with MVC's vaccine research expertise to support IND applications and future global clinical development, with plans to explore further opportunities across other vaccine programs.
Charles River (NYSE: CRL) officer to sell 2,039 shares after option exercise
An officer of Charles River Laboratories International, Inc. (NYSE: CRL), Shannon M. Parisotto, plans to sell 2,039 common shares after exercising stock options, as detailed in a Form 144 SEC filing. UBS Financial Services Inc. is acting as the broker for this transaction. The filing also indicates previous sales by Parisotto within the last three months, totaling 5,046 and 3,714 units, respectively.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) stock rose 3.87% to $290.00 on Wednesday, outperforming the S&P 500 Index and Dow Jones Industrial Average. The company also hit a new 52-week high, surpassing its previous peak. This strong performance occurred during a generally positive trading session for the stock market.
Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued?
Charles River Laboratories International (CRL) recently cut its 2026 earnings guidance after reporting a net loss and lower revenue in Q2, yet its share price has seen strong recent gains. Despite these financial setbacks, the company's stock is considered 11% undervalued with a fair value of $313.61, largely due to its acquisition of a Cambodian primate supplier to secure access to critical non-human primate supply for drug development. This acquisition addresses a hidden bottleneck in pharmaceutical research, supporting the higher fair value narrative despite inherent risks related to primate supply conditions or regulatory changes.
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell by 2.60% on Tuesday, closing at $279.19, significantly underperforming broader market indices like the S&P 500 and Dow Jones Industrial Average. The company's shares are now 3.35% below their 52-week high reached the day prior. This decline occurred during a generally down day for the stock market.
Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations
Charles River Labs stock has reached a new 12-month high, driven by strong Q2 2026 results and upgraded full-year guidance targeting double-digit EPS and increased free cash flow. The company's stock, trading around $288.42, has gained 43.56% over the past year, although current prices exceed the average analyst price target of $255.65. While the positive outlook underscores investor confidence in the company's preclinical services, a recent Form 144 filing by insiders suggests some profit-taking at elevated valuations.
Charles River (NYSE: CRL) investor to sell 573 shares via UBS
Nancy C. Andrews, a holder of Charles River Laboratories International, Inc. (CRL), has filed a Rule 144 notice for the proposed sale of 573 common shares through UBS Financial Services Inc. The shares, valued at $163,305, represent a small fraction of the 48,167,730 shares outstanding and were acquired via a stock option exercise on August 18, 2026. The sale is approximated for the same date.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock rise by 2.35% to $286.64 on Monday, despite a general market downturn where both the S&P 500 and Dow Jones Industrial Average fell. This performance broke a two-day losing streak for the company's shares.
Resilient Charles River Labs stock hits new 12-month high as Q2 revenue tops $1 billion
Charles River Labs stock reached a new 12-month high of $288.64 on August 17, 2026, driven by its Q2 2026 earnings performance. Despite a 2.7% year-over-year revenue decline to $1.00 billion, the company surpassed analyst expectations for both revenue and EPS, leading to a 19.6% stock increase since the report. Analysts currently have a "moderate buy" consensus, with an average price target below the current trading price, suggesting that much of the future growth is already priced in.
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High - Here's Why
Charles River Laboratories International (NYSE:CRL) hit a new 52-week high, trading as high as $288.64 and closing above its moving averages. Despite a "Moderate Buy" consensus from analysts, recent ratings vary, and insiders have sold approximately $31.8 million in shares over the past 90 days. The company exceeded quarterly EPS and revenue expectations, though revenue saw a slight year-over-year decline.
Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL
Handelsbanken Fonder AB increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the second quarter, now owning 19,306 shares valued at $4.38 million. This comes as the company reported strong quarterly earnings, beating estimates with an EPS of $3.02, though revenue saw a slight year-over-year decline. Despite positive analyst sentiment and maintained fiscal 2026 EPS guidance, company insiders sold approximately $31.8 million worth of stock in the last 90 days.
Lowered 2026 EPS Outlook and Rebounding Demand Could Be A Game Changer For Charles River (CRL)
Charles River Laboratories International (CRL) reported second-quarter results with a lowered 2026 GAAP EPS guidance and a projected revenue decline, primarily due to divestiture-related losses. Despite this, management highlighted a return to organic revenue growth and improving demand in its Discovery and Safety Assessment segment. The company's ongoing share repurchase program and the potential for sustained growth in DSA are key factors shaping its investment narrative amidst short-term GAAP losses.
Lowered 2026 EPS Outlook and Rebounding Demand Could Be A Game Changer For Charles River (CRL)
Charles River Laboratories International reported Q2 2026 results with a small net loss and lowered its 2026 GAAP EPS guidance, largely due to divestitures. Despite this, management noted a return to organic revenue growth and improving demand in its Discovery and Safety Assessment segment. The article suggests that this recovery, alongside an ongoing share repurchase program, could reshape the company's investment narrative, though analyst views on future profitability vary.
Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock
Birgit Girshick, CEO of Charles River Laboratories International (NYSE:CRL), sold 6,500 shares of the company's stock for approximately $1.82 million. This transaction, executed under a Rule 10b5-1 trading plan, reduced her ownership by 15.29%. The company recently reported strong quarterly EPS and revenue that beat consensus estimates but saw a year-over-year revenue decline, while analysts maintain a "Moderate Buy" rating with an average price target of $255.65.
Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock
Charles River Laboratories International's EVP, Shannon Parisotto, sold 3,714 shares of company stock for approximately $1.04 million, reducing her holdings by 43.59%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan. The company recently reported adjusted earnings of $3.02 per share, exceeding estimates, with revenue of $1 billion, and has maintained its fiscal 2026 EPS guidance.
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell 1.09% to $281.27 on Thursday, despite a positive trading session for the broader market. This underperformance snapped a seven-day winning streak for the company's shares. The S&P 500 Index rose 0.65%, and the Dow Jones Industrial Average gained 0.13% on the same day.
Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan
Charles River Laboratories (CRL) CEO Birgit Girshick exercised stock options for 6,500 shares on August 11, 2026, at an exercise price of $179.66 per share. Simultaneously, she sold these 6,500 common shares at $279.90 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 3, 2025, and after the sale, Girshick holds 43,803 common shares indirectly through a revocable trust.
Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan
Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories International, exercised stock options for 3,714 shares at $179.66 per share and simultaneously sold the same number of shares at $279.66 per share. These transactions, executed on August 11, 2026, were conducted under a Rule 10b5-1 Trading Plan adopted on March 4, 2026. Following these sales, Parisotto's indirect holdings include 9,680 shares in a trust and 28,510 shares held by Karpathos Investments LLC.
Invesco reports 2.98M-share stake in Charles River Laboratories (CRL)
Invesco Ltd., a Bermuda-based parent holding company, has reported a significant passive ownership position in Charles River Laboratories International, Inc. (CRL) common stock. The firm beneficially owns 2,984,785 shares, representing 6.2% of the outstanding common stock, held by its investment advisory clients. Invesco maintains sole voting power over 2,955,113 shares and sole dispositive power over all 2,984,785 shares, with no single underlying client holding more than 5% economic ownership.
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock
Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of the company, which holds a "Moderate Buy" consensus rating from analysts.
Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH
This article compares two healthcare ETFs: State Street's SPDR S&P Pharmaceuticals ETF (XPH) and Invesco's S&P 500 Equal Weight Health Care ETF (RSPH). XPH focuses specifically on pharmaceuticals and has shown higher returns but also higher volatility, while RSPH offers broader, equal-weighted exposure to the entire S&P 500 healthcare sector. The choice between them depends on an investor's goals and risk tolerance, with XPH suitable for targeted pharmaceutical exposure and RSPH for diversified healthcare investment.
Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com
Charles River Laboratories International Inc. (CRL) stock has reached a 52-week high of $285.13, reflecting an 83.28% increase over the past year and a 41.4% year-to-date return. This surge follows strong second-quarter earnings that surpassed analyst expectations and led to increased price targets from several analyst firms, despite InvestingPro suggesting the stock may be overvalued.
Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH
This article compares two healthcare-focused ETFs: State Street's SPDR S&P Pharmaceuticals ETF (XPH) and Invesco's S&P 500 Equal Weight Health Care ETF (RSPH). XPH focuses specifically on the pharmaceutical industry and has shown stronger recent performance, while RSPH offers broader, equal-weighted exposure to the entire S&P 500 healthcare sector. The choice between them depends on an investor's preference for focused pharmaceutical exposure versus diversified healthcare coverage, considering factors like expense ratios, volatility, and historical returns.
Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.
Pacer Advisors Inc. significantly reduced its stake in Charles River Laboratories International (NYSE: CRL) by 98.4% in the first quarter, selling over 151,000 shares. Despite this, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and a $255.65 average price target. The company reported strong Q1 earnings that beat expectations, although revenue saw a slight year-over-year decline, and several insiders also sold shares.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock advance by 1.81% to $282.00 on Tuesday, marking its sixth consecutive day of gains. This performance stood out on a generally grim trading day where the S&P 500 Index fell 0.32% and the Dow Jones Industrial Average dropped 0.34%.
Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock
Charles River Laboratories International Director James Foster sold 28,733 shares of NYSE:CRL stock for approximately $7.9 million at an average price of $275, reducing his direct ownership by 47.63%. This transaction, conducted under a pre-arranged Rule 10b5-1 trading plan, comes amidst generally positive analyst sentiment for CRL, with a consensus "Moderate Buy" rating, despite a year-over-year revenue decline and negative net margin reported in its latest quarterly results. Other executive stock sales and the stock's recent strong rally may influence investor sentiment.
Charles River Laboratories (CRL) EVP LaPlume reports bona fide gift of 257 shares
Joseph W. LaPlume, EVP, Corp Strategy & Develop at Charles River Laboratories International, Inc. (CRL), reported a bona fide gift of 257 shares of common stock on August 10, 2026. This transaction was a disposition at a reported per-share price of $0.00, leaving LaPlume with 31,041 shares of direct ownership. The Form 4 filing indicates this was a genuine gift and not conducted under a Rule 10b5-1 trading plan.
Charles River (CRL) director James C. Foster exercises options and sells 28,733 shares
Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares at $179.66 per share and immediately sold them at $275.00 per share on August 10, 2026, pursuant to a Rule 10b5-1 Trading Plan. This transaction resulted in an approximate pre-tax spread of $2.74 million. Following the sale, Foster maintains indirect holdings of common stock through various trusts.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing (Aug 11, 2026)
This SEC filing (Form 144) for Charles River Laboratories International, Inc. (CRL) details a proposed sale of 6,500 shares of common stock, valued at $1,819,350.00, acquired through the exercise of stock options on August 11, 2026. The transaction was handled by UBS Financial Services, Inc. and is scheduled for the same day.
Charles River Labs SVP Michael Knell sells $1.73m in stock
Michael Knell, SVP, Finance and Chief Accounting Officer at Charles River Laboratories International (NASDAQ:CRL), sold 6,645 shares totaling approximately $1.73 million on August 6, 2026, with prices ranging from $258.53 to $265.17 per share. On the same day, he acquired 2,345 shares through stock options for about $459,909. These transactions occurred as the stock neared its 52-week high, with InvestingPro indicating it might be overvalued, despite recent positive earnings and analyst upgrades.
Charles River Labs SVP Michael Knell sells $1.73m in stock
Michael Knell, SVP at Charles River Laboratories, sold 6,645 shares worth approximately $1.73 million, while simultaneously acquiring 2,345 shares through stock options. This follows the company's strong second-quarter 2026 earnings, which
Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?
Charles River Laboratories International (CRL) has cut its 2026 GAAP earnings guidance and reported a quarterly net loss, yet its share price has seen strong momentum recently. While one narrative suggests the stock is 14.7% undervalued based on its acquisition of a primate supplier, another view, using a DCF model, indicates it might be significantly overvalued. Investors are encouraged to assess the data and make their own judgments.
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of "Moderate Buy" by Brokerages
Charles River Laboratories International (NYSE:CRL) has received an average "Moderate Buy" rating from sixteen brokerages, with an average 12-month price target of $255.65. This follows the company exceeding quarterly earnings expectations with an adjusted EPS of $3.02 and revenue of $1.0 billion. Despite recent insider selling, institutional investors hold a significant majority of the stock.
TD Cowen Reaffirms Their Buy Rating on Charles River Labs (CRL)
TD Cowen analyst Charles Rhyee has maintained a Buy rating on Charles River Labs (CRL) with a price target of $300.00. Rhyee, a 4-star analyst, has a 53.25% success rate and an average return of 5.5% in the Healthcare sector. The broader analyst consensus for Charles River Labs is a Strong Buy, with an average price target of $281.55.
Victoria Creamer Sells 4,179 Shares of Charles River Laboratories International (NYSE:CRL) Stock
Victoria Creamer, EVP of Charles River Laboratories International (NYSE:CRL), sold 4,179 shares for over $1.08 million, reducing her holdings by 12.21%. Despite the insider sale, the company recently reported strong quarterly earnings, beating estimates with $3.02 EPS and $1 billion in revenue, and analysts maintain a "Moderate Buy" rating with several raised price targets. CRL's stock rose 3.3% to $276.34 following these developments.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Shares of Charles River Laboratories International Inc. (CRL) rose 3.56% to $277.00 on Monday, marking its fifth consecutive day of gains. This strong performance occurred on a generally grim trading day where both the S&P 500 Index and Dow Jones Industrial Average experienced slight declines. The article highlights CRL's stock outperformance against the broader market.
Michael Gunnar Knell Sells 6,645 Shares of Charles River Laboratories International (NYSE:CRL) Stock
Michael Gunnar Knell, Chief Accounting Officer at Charles River Laboratories International (NYSE:CRL), recently sold 6,645 shares of the company's stock for approximately $1.73 million, reducing his stake by 35.92%. Despite this insider selling, the company reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts with a target price of $255.65. The stock is currently trading near its 52-week high, and institutional investors have shown increased interest, acquiring new or boosting existing stakes.
Charles River (CRL) finance chief sells 6,645 shares after exercising 2,345 options
Michael Gunnar Knell, SVP of Finance and Chief Accounting Officer at Charles River Laboratories International, Inc. (CRL), reported exercising 2,345 stock options and selling 6,645 shares of common stock on August 6, 2026. The options were exercised at strike prices between $179.66 and $208.44, while the shares were sold at prices ranging from $258.53 to $265.17. These transactions resulted in approximately $1.73 million in gross sale proceeds, with an exercise cost of about $460,000.
James Foster (CRL) files Form 144 for 28,733-share option sale
James Foster, an insider at Charles River Laboratories International, Inc. (CRL), has filed a Form 144 indicating his plan to sell 28,733 shares of common stock. These shares will be acquired through the exercise of stock options for cash on August 10, 2026, with an aggregate market value of $7,901,575.00. Over the past three months, Foster previously sold 75,000 shares for $16,875,000.00.
Charles River (CRL) EVP Victoria Creamer exercises options and sells 4,179 shares
Victoria L. Creamer, EVP & Chief People Officer of Charles River Laboratories International, Inc. (CRL), exercised stock options for 4,179 shares at $179.66 per share and immediately sold them for $259.16 per share on August 6, 2026. This transaction resulted in approximately $332K pre-tax spread from the exercise and sale. Following the transaction, Creamer holds 30,051 shares of common stock directly, with no derivative shares remaining from this specific grant.
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $291.46, Implies 9% Upside
Analysts have raised the 12-month average price target for Charles River Laboratories International, Inc. (CRL) stock from $285.54 to $291.46, implying a 9% potential upside based on its August 7th closing price. The consensus rating from 19 analysts remains "Buy," with a majority recommending purchasing the stock. Investors can find more detailed price target data and analyst recommendations on the Forecasts tab and in the dedicated News Flow section.
